GlassScriptPhysician profile
Michael S Milner
NPI 1851359079
$2,308.88
in general payments reported to CMS, 2019-2025
18 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $183 · 2021: $334 · 2022: $286 · 2023: $442 · 2024: $467 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $408.57 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $388.54 | 2019-2025 | Cequa |
| Abbvie INC. | $348.92 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $253.42 | 2020-2023 | |
| Alcon Vision LLC | $186.94 | 2020-2025 | Tryptyr, Rocklatan, Clareon Panoptix Pro |
| Allergan, INC. | $137.85 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.31 | 2019-2021 | |
| Harrow Eye, LLC | $91.71 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $87.95 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $75.89 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $37.23 | 2019-2021 | |
| Tearlab Corp | $32.49 | 2021-2024 | Scoutpro Osmolarity System |
| Oyster Point Pharma, INC. | $29.68 | 2023 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $26.32 | 2024 | Cirrus Hd-Oct |
| Johnson & Johnson Surgical Vision, INC. | $22.79 | 2023 | Tecnis Simplicity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $14.71 | 2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Milner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.